Designation of Adalimumab (Humira) as an orphan drug by Abbvie Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods, including medicines, medical devices, and blood and tissues, with the aim of ensuring that these products are safe, of high quality, and effective. The Act provides the legal framework for the regulation of therapeutic goods, ensuring that they meet required standards of safety, quality, and efficacy. The Act was introduced to address the need for a comprehensive legislative framework to regulate therapeutic goods, ensuring that they are safe and effective for use by the Australian public. The Therapeutic Goods Administration (TGA) is the body responsible for administering the Act, and its policy objective is to protect and promote public health by regulating therapeutic goods. This particular Gazette from the TGA designates Adalimumab (HUMIRA) as an orphan drug for the treatment of paediatric Enthesitis-Related Arthritis (paediatric ERA), recognising the need for specialised treatments for rare conditions and providing an incentive for the development of such treatments.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Department of Health through the Therapeutic Goods Administration, applies to the regulation of therapeutic goods in Australia. Specifically, the designation of Adalimumab (HUMIRA) as an orphan drug for the treatment of paediatric Enthesitis-Related Arthritis (paediatric ERA) under the Therapeutic Goods Regulations 1990 targets medical entities, particularly Abbvie Pty Ltd as the sponsor of the drug, and healthcare professionals involved in prescribing and administering the treatment. This designation is intended to encourage the development of drugs for rare diseases that affect a small number of patients. The application of this Act is national, covering all states and territories within the Commonwealth of Australia. There are no stated exclusions or exemptions in this particular designation; however, the application of the broader Therapeutic Goods Act and Regulations may include various exclusions and thresholds that cater to different classes of therapeutic goods. Subordinate instruments may further extend or restrict the application of this Act by providing additional details on the approval and monitoring of therapeutic goods designated as orphan drugs.

Key Provisions

The Therapeutic Goods Act 1989, in this instance, designates Adalimumab (HUMIRA) as an orphan drug (s 16J of the Therapeutic Goods Regulations 1990). Specifically, section 16J(2) of the Regulations empowers the Delegate of the Secretary to designate a drug as an orphan drug if it is intended for the treatment of a rare medical condition. In this case, Adalimumab (HUMIRA) has been designated for the treatment of paediatric Enthesitis-Related Arthritis (paediatric ERA), a rare condition in children. The drug is provided in a solution for injection form. This legislative action aims to encourage the development of treatments for rare diseases by providing certain incentives, including the orphan drug designation. The designation of Adalimumab (HUMIRA) as an orphan drug imposes several obligations on the parties involved, particularly the sponsor, Abbvie Pty Ltd. The sponsor must ensure that the drug is manufactured and marketed in compliance with all relevant regulations and standards. This includes adhering to the quality, safety, and efficacy requirements stipulated in the Therapeutic Goods Act and the Therapeutic Goods Regulations. Additionally, the sponsor must provide accurate and comprehensive information about the drug, including its intended use, potential side effects, and proper administration, to healthcare professionals and consumers. The sponsor is also required to report any adverse events or issues related to the drug to the Therapeutic Goods Administration. Failure to comply with the provisions of the Therapeutic Goods Act and the Therapeutic Goods Regulations can result in significant legal consequences. For the sponsor, non-compliance may lead to enforcement actions, including fines, product recalls, or even the suspension or cancellation of the therapeutic goods authorisation. In severe cases, breaches of the Act may result in criminal charges. For instance, section 33DA of the Therapeutic Goods Act outlines the penalties for contravening certain provisions of the Act, which can include substantial fines for corporations (up to $2.1 million for serious offences) and imprisonment for individuals (up to five years). These penalties underscore the importance of adhering to the regulatory framework to ensure the safety and efficacy of therapeutic goods in Australia.